APLT | tickerfilter.com

Fundamental analysis

33%

Profitability 25%

Dept financing 25%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-20.53%

1 Month

-32.53%

3 Months

-49.11%

6 Months

-95.79%

1 Year

-93.80%

2 Year

-55.64%

Key data

Stock price

$0.35

P/E Ratio

0.00

DAY RANGE

$0.34 - $0.42

EPS

-$1.53

52 WEEK RANGE

$0.34 - $10.62

52 WEEK CHANGE

-$93.72

MARKET CAP

976.193 M

YIELD

N/A

SHARES OUTSTANDING

114.846 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

2.29

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,760,927

AVERAGE 30 VOLUME

$1,843,587

Company detail

CEO: Shoshana Shendelman
Region: US
Website: www.appliedtherapeutics.com
Employees: 30
IPO year: 2019

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosmia in healthy volunteers and adults. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for treatment of diabetic peripheral neuropathy.

APLT - Applied Therapeutics, Inc.